Chest 2005, 128:452–462.PubMedCrossRef 18. Petersen S, Aninat-Meyer M, Schluns K, Gellert K, Dietel M, Petersen I: Chromosomal alterations in the clonal evolution to the metastatic stage of squamous cell carcinomas of the lung. Br J Cancer 2000, 82:65–73.PubMedCrossRef

19. Ubagai T, Matsuura S, Tauchi H, Itou K, Komatsu K: Comparative genomic hybridization analysis suggests a gain of chromosome 7p associated with lymph node metastases in non-small cell lung cancer. Oncol Rep 2001, 8:83–88.PubMed 20. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K: Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 2008, 99:929–935.PubMedCrossRef A-1210477 21. Monaco SE, Nikiforova MN, Cieply

K, Teot LA, Khalbuss WE, Dacic S: A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol 2010, 41:94–102.PubMedCrossRef 22. Italiano A, Vandenbos FB, Otto J, Mouroux J, Fontaine D, Marcy PY, Cardot N, Thyss A, Pedeutour F: Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol 2006, XAV-939 clinical trial 17:981–985.PubMedCrossRef 23. Bozzetti C, Tiseo M, Lagrasta C, Nizzoli R, Guazzi A, Leonardi F, Gasparro D, Spiritelli E, Rusca M, Carbognani P, et al.: Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites. J Thorac Oncol 2008, 3:18–22.PubMedCrossRef 24. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, Mavroudis D, Voutsina A: Comparison of EGFR and K-RAS gene status between primary tumours and corresponding

metastases in NSCLC. Br J Cancer 2008, 99:923–929.PubMedCrossRef 25. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, et al.: Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastases in non-small cell lung cancer. J Thorac Oncol 2009, 4:809–815.PubMedCrossRef 26. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M: EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional Thalidomide lymph node metastases. Clin Cancer Res 2009, 15:4554–4560.PubMedCrossRef 27. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228–247.PubMedCrossRef 28. Bernards R, Weinberg RA: A progression puzzle. Nature 2002, 418:823.PubMedCrossRef 29. Cortot AB, Italiano A, Burel-Vandenbos F, Martel-Planche G, Hainaut P: KRAS see more mutation status in primary nonsmall cell lung cancer and matched metastases.